SCHEMBL2004850

SCHEMBL2004850

Cc1n[nH]c2cccc(OCc3ccccc3)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGMS2 Q8NHU3 1/20 0.55
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
BRD4 O60885 3/20 0.50
HTR2A P28223 2/20 0.48
EDNRA P25101 1/20 0.45
DCPS Q96C86 1/20 0.45
STAT3 P40763 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13122661 0.89 MEN1 (0.49) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL13122181 0.87 L3MBTL1 (0.47) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL13122037 0.84 SGMS2 (0.42) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL21266902 0.82 SGMS2 (0.55) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL13190080 0.79 CDK8 (0.49) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL3778607 0.78 L3MBTL1 (0.47) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL26811483 0.78 SGMS2 (0.51) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL26811444 0.78 HTR2A (0.62) SGMS2MAPTMAPK1TDP1L3MBTL1
SCHEMBL12907163 0.76 CDK5 (0.49) SGMS2DCPSHTTSMN1; SMN2MAPK14
SCHEMBL26811294 0.76 SGMS2 (0.49) SGMS2MAPTMAPK1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB SGMS2 3020/4885MAPT 2061/4885MAPK1 4030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.